

Sanofi Foreign Participations B.V
(Formerly known as Zentiva NV)

26th November 2018

To: Mr. Muhammad Yousuf,
Company Secretary,
Sanofi-Aventis Pakistan Ltd.,
Sanofi Pakistan,
Plot 23, Sector 22,
Korangi Industrial Area, Karachi;

To: The General Manager,
Pakistan Stock Exchange,
Stock Exchange Building,
Stock Exchange Road,
Karachi-74000, Pakistan.
Tel: +9221 111-001122

To: The Registrar,
Securities & Exchange Commission of Pakistan,
Fourth Floor, State Life Building No. 2,
North Wing, Wallace Road,
I. I. Chundrigar Road,
Karachi,

DISCLOSURE UNDER SECTION 110, OF THE
SECURITIES ACT, 2015

Dear Sir,

Sanofi Foreign Participations B.V formerly Zentiva NV has, by transfer deed, acquired from SECIPE, 5,099,469 (five million, ninety nine thousand, four hundred and sixty nine) shares of Sanofi-Aventis Pakistan Ltd., a company limited by shares and listed on the Pakistan Stock Exchange, which constitutes 52.87% in value of the total issued share capital of Sanofi-Aventis Pakistan Ltd.

The transferor (i.e. SECIPE) and we, the transferee (i.e. Sanofi Foreign Participations B.V formerly Zentiva NV), are both wholly owned subsidiaries of Sanofi S.A. (in the case of Sanofi Foreign Participations B.V formerly Zentiva NV, through Sanofi S.A.'s wholly owned subsidiary, Sanofi Aventis Europe. Therefore Sanofi S.A. remains the ultimate beneficial owner of these shares. In the circumstances, the exclusion specified in Section 109(1)(h)(iii) of the Securities Act, 2015 will apply, and thus this disclosure constitutes the extent of the compliance called for under Part IX of the Securities Act, 2015.



Colette Mutschler



Sincerely,

Sanofi Foreign Participations B.V
(Formerly Zentiva NV)

Peter Oldenzien